nivolumab,cabozantinib
bms
['opdivo', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'renal,(-adrenal)', 'cabometyx', 'bms']
#bms presented three-year follow-up data of #opdivo plus #cabometyx combination, which showed sustained survival as a first-line therapy for advanced #renalcellcarcinoma. #news #media #gu23 #ascogu23 #asco23 #ascogu2023 #asco #kidneycancer #conferences
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news plus #blogs #diseases #drugs #healthcaresystems #globalhealth #pharma